This episode’s guest, Melinda Mayorga, RN, MSN, CNS, AGCNS-BC, OCN, a clinical nurse specialist at Norris Comprehensive ...

Oncology nurses and APPs are key players in patient education on precision medicine.

The FDA has approved the use of subcutaneous amivantamab and hyaluronidase-lpuj (Rybrevant Faspro) for use in all approved ...

CAR T-cell therapy has revolutionized the treatment of certain hematologic malignancies, providing durable remissions for ...

The FDA has granted accelerated approval to subcutaneous treatment with mosunetuzumab (Lunsumio VELO™), a CD20xCD3 bispecific antibody, for adult patients with relapsed or refractory follicular ...

Young, Empowered, and Strong (YES), a mobile health intervention, was linked to improved general and cancer-specific ...

Hormone replacement therapy (HRT) does not have an adverse effect on breast cancer risk, according to findings from an ...

The FDA has granted standard approval to rucaparib (Rubraca) for the treatment of patients with metastatic ...

The FDA has greenlit niraparib and abiraterone acetate (AAP; Akeega) with prednisone for the treatment of adults with deleterious or suspected deleterious BRCA2 -mutated metastatic hormone-sensitive ...

From clinical trials, to psychosocial needs, to care transitioning, adolescent and young adult patients with cancer face unique challenges that set them apart from the general adult and pediatric ...

Race was identified as an independent prognostic factor in patients with AML receiving intensive chemotherapy.

Transitioning the dose of axatilimab (Niktimvo) from 0.3 mg/kg every 2 weeks to 0.6 mg/kg every 4 weeks appeared feasible in patients with chronic graft-versus-host disease (cGVHD), according to data ...